We appreciate the insightful commentary by Xu et al. on our report of neoadjuvant nivolumab plus ipilimumab in patients with potentially resectable hepatocellular carcinoma (HCC)(1).
The three knowledge gaps pointed out by Xu et al. indeed reflect the most critical issues for future research in this rapidly evolving field.
Journal of Hepatology published a clinical update in Research Highlights on 17 Mar 2026.
The item focuses on Response to “Conversion surgery as a missing outcome in first-line immunotherapy trials for hepatocellular carcinoma”.
Review the original article for the full source wording and details.